Cantor Fitzgerald Raises Supernus Pharmaceuticals (NASDAQ:SUPN) Price Target to $67.00

Supernus Pharmaceuticals (NASDAQ:SUPN) had its price objective raised by research analysts at Cantor Fitzgerald from $63.00 to $67.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 38.26% from the company’s current price.

Several other brokerages also recently commented on SUPN. Zacks Research raised shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Finally, Wall Street Zen raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 4th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $62.83.

Supernus Pharmaceuticals Stock Down 0.6%

Shares of Supernus Pharmaceuticals stock opened at $48.46 on Thursday. The stock has a market cap of $2.81 billion, a price-to-earnings ratio of -95.02, a P/E/G ratio of 1.04 and a beta of 0.54. Supernus Pharmaceuticals has a twelve month low of $32.20 and a twelve month high of $59.68. The company’s fifty day moving average is $47.10 and its 200 day moving average is $49.49.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Several large investors have recently modified their holdings of the business. Sit Investment Associates Inc. lifted its holdings in Supernus Pharmaceuticals by 0.4% during the 4th quarter. Sit Investment Associates Inc. now owns 65,200 shares of the specialty pharmaceutical company’s stock worth $3,240,000 after purchasing an additional 250 shares in the last quarter. Summit Global Investments lifted its stake in Supernus Pharmaceuticals by 6.1% in the 1st quarter. Summit Global Investments now owns 4,436 shares of the specialty pharmaceutical company’s stock worth $229,000 after purchasing an additional 256 shares in the last quarter. Maryland State Retirement & Pension System boosted its holdings in Supernus Pharmaceuticals by 3.6% in the 4th quarter. Maryland State Retirement & Pension System now owns 8,351 shares of the specialty pharmaceutical company’s stock valued at $415,000 after purchasing an additional 290 shares during the period. SummitTX Capital L.P. increased its holdings in shares of Supernus Pharmaceuticals by 2.7% in the fourth quarter. SummitTX Capital L.P. now owns 11,670 shares of the specialty pharmaceutical company’s stock worth $580,000 after purchasing an additional 303 shares during the period. Finally, PNC Financial Services Group Inc. boosted its stake in Supernus Pharmaceuticals by 2.3% during the first quarter. PNC Financial Services Group Inc. now owns 14,548 shares of the specialty pharmaceutical company’s stock valued at $752,000 after buying an additional 321 shares during the period.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained?release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended?release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended?release capsules), approved for the treatment of attention?deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.